BiochemProbe — Life Science Research Reagents

Vazegepant free base · Synonyms: BHV-3500 | Zavegepant

Vazegepant is the first intranasal CGRP receptor antagonist.

For research use only. Not for human or veterinary use.

Target CGRP Receptor
Research area Neurological Disease
Purity >98% Stock Inquire

Vazegepant structure

CAS No.: 1337918-83-8

Download structure (.mol)

Pack sizes & pricing

Size Price SKU Stock
100 mg USD 420.00 BP-01869-100mg In stock Get quote
250 mg USD 720.00 BP-01869-250mg In stock Get quote
500 mg USD 1,120.00 BP-01869-500mg In stock Get quote
1 g USD 1,720.00 BP-01869-1g In stock Get quote
5 g Inquire BP-01869-5g Inquire Inquire

Need another size or custom synthesis? Request a quote.

Description

Vazegepant is the first intranasal CGRP receptor antagonist for the study the acute research of migraine.

Biological activity

In Vitro Vazegepant (Zavegepant) exhibits fully competitive binding activity to the human CGRP receptor expressed endogenously in the SKN-MC cell membrane, with a Ki of 23 pM, which is more than 10,000 times more selective than the adrenal medullary receptor 1/2, calcitonin receptor, and amyloid receptor 1/3; and can strongly and completely reverse the vasodilatory effect induced by CGRP in isolated human intracranial arterial tissue, with an EC50 of 880 pM. In Vivo Vazegepant (Zavegepant) (0.03 mg/kg; subcutaneous administration; 15-105 min) significantly inhibited CGRP-induced facial blood flow elevation in a marmoset model. Vazegepant exhibited low oral bioavailability in monkey (F = 0.3%), mouse (F = 1.4%), and rat (F = 1.7%) animal models. Vazegepant (nasal administration) was rapidly absorbed in a rabbit model, with a Tmax of 15-20 min.

Identifiers

SMILES
O=C(N1CCC(C2=CC3=C(NC2=O)C=CC=C3)CC1)N[C@H](CC4=CC5=C(NN=C5)C(C)=C4)C(N6CCN(C7CCN(C)CC7)CC6)=O
InChIKey
JJVAPHYEOZSKJZ-JGCGQSQUSA-N

Specifications

MW (average)
638.8022
Formula
C36H46N8O3
CAS No.
1337918-83-8
Physical state
Solid
Color
White to off-white
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
Powder 4°C, protect from light; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO 50 mg/mL

References

[1]. Leonard KA, et al. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2020 Mar 26;63(6):2915-2929.
[2]. Gene M Dubowchik,Charles M Conway,Alison W Xin.Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.

Same research area

Search Neurological Disease